CD274 and cancer: PD-1/PD-L1 The essence of immune checkpoint inhibitors is that they can inhibit or block the binding between PD-1 and PD-L1 to enable the body to recognize and kill cancer cells by reasserting immune function, thus achieving a therapeutic effect on cancer (Shen and Zhao, 2018; Yi et al., 2022).